Increasing platelets without transfusion: Is it time to introduce novel thrombopoietic agents in neonatal care

Journal of Perinatology

Volumn 30, Issue 12, 2010, Pages 765-769

  Sallmon, H ^a,b   Gutti, R K ^a   Ferrer Marin, F ^a,c   Liu, Z J ^a   Sola Visner, M C ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

neonate; thrombocytopenia; thrombopoietic growth factors; thrombopoietin

Indexed keywords

ELTROMBOPAG; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; ROMIPLOSTIM;

CRITICALLY ILL PATIENT; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NEONATAL THROMBOCYTOPENIA; NEWBORN CARE; NEWBORN INTENSIVE CARE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; RESPIRATION DEPRESSION; REVIEW; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS;

ADULT; AGE FACTORS; APOPTOSIS; BENZOIC ACIDS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; HUMANS; HYDRAZINES; INFANT, NEWBORN; NEURONS; PATIENT SELECTION; PLATELET TRANSFUSION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE; THROMBOPOIESIS; THROMBOPOIETIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78649666559     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2010.50     Document Type: Review

References (45)

1. Bishara N, Ohls RK. Current controversies in the management of the anemia of prematurity. Semin Perinatol 2009; 33: 29-34.
2. Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood Rev 2008; 22: 173-186.
3. Christensen RD, Calhoun DA. Congenital neutropenia. Clin Perinatol 2004; 31: 29-38.
4. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001; 108: 934-942.
5. Bernstein HM, Calhoun DA, Christensen RD. Use of myeloid colony-stimulating factors in neonates with septicemia. Curr Opin Pediatr 2002; 14: 91-94.
6. Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99: 2599-2602.
7. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
8. Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet 2009; 373: 1562-1569.
9. George JN, Terrell DR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica 2008; 93: 1445-1449.
10. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672-1681.
11. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
12. Christensen RD, Henry E, Wiedmeier SE, Stoddard RA, Sola-Visner MC, Lambert DK et al. Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 2006; 26: 348-353. (Pubitemid 43811510)
13. Josephson CD, Su LL, Christensen RD, Hillyer CD, Castillejo MI, Emory MR et al. Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey. Pediatrics 2009; 123: 278-285.
14. Del Vecchio A, Sola MC, Theriaque DW, Hutson AD, Kao KJ, Wright D et al. Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 2001; 41: 803-808.
15. Baer VL, Lambert DK, Henry E, Snow GL, Sola-Visner MC, Christensen RD. Do platelet transfusions in the NICU adversely affect survival? Analysis of 1600 thrombocytopenic neonates in a multihospital healthcare system. J Perinatol 2007; 27: 790-796.
16. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115: 3339-3347.
17. Levine RF, Olson TA, Shoff PK, Miller MK, Weisman LE. Mature micromegakaryocytes: an unusual developmental pattern in term infants. Br J Haematol 1996; 94: 391-399.
18. Olson TA, Levine RF, Mazur EM, Wright DG, Salvado AJ. Megakaryocytes and megakaryocyte progenitors in human cord blood. Am J Pediatr Hematol Oncol 1992; 14: 241-247.
19. Mattia G, Vulcano F, Milazzo L, Barca A, Macioce G, Giampaolo A et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 2002; 99: 888-897.
20. Murray NA, Watts TL, Roberts IA. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998; 43: 148-151.
21. Nishihira H, Toyoda Y, Miyazaki H, Kigasawa H, Ohsaki E. Growth of macroscopic human megakaryocyte colonies from cord blood in culture with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on frequency of colonies. Br J Haematol 1996; 92: 23-28.
22. Harker LA. Kinetics of thrombopoiesis. J Clin Invest 1968; 47: 458-465.
23. Harker LA. Thrombokinetics in idiopathic thrombocytopenic purpura. Br J Haematol 1970; 19: 95-104.
24. Sola-Visner MC, Christensen RD, Hutson AD, Rimsza LM. Megakaryocyte size and concentration in the bone marrow of thrombocytopenic and nonthrombocytopenic neonates. Pediatr Res 2007; 61: 479-484.
25. Hu Z, Slayton WB, Rimsza LM, Bailey M, Sallmon H, Sola-Visner MC. Differences between newborn and adult mice in their response to immune thrombocytopenia. Neonatology 2010; 98: 100-108.
26. Sola MC, Calhoun DA, Hutson AD, Christensen RD. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999; 104: 90-92.
27. Sola MC, Dame C, Christensen RD. Toward a rational use of recombinant thrombopoietin in the neonatal intensive care unit. J Pediatr Hematol Oncol 2001; 23: 179-184.
28. Murray NA, Howarth LJ, McCloy MP, Letsky EA, Roberts IA. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002; 12: 35-41.
29. Dame C. Developmental biology of thrombopoietin in the human fetus and neonate. Acta Paediatr Suppl 2002; 91: 54-65.
30. Garcia MG, Duenas E, Sola MC, Hutson AD, Theriaque D, Christensen RD. Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 2001; 21: 415-420.
31. Dohner ML, Wiedmeier SE, Stoddard RA, Null Jr D, Lambert DK, Burnett J et al. Very high users of platelet transfusions in the neonatal intensive care unit. Transfusion 2009; 49: 869-872.
32. Brown RE, Rimsza LM, Pastos K, Young L, Saxonhouse MA, Bailey M et al. Effects of sepsis on neonatal thrombopoiesis. Pediatr Res 2008; 64: 399-404.
33. Fleming GM, Gurney JG, Donohue JE, Remenapp RT, Annich GM. Mechanical component failures in 28,171 neonatal and pediatric extracorporeal membrane oxygenation courses from 1987 to 2006. Pediatr Crit Care Med 2009; 10: 439-444.
34. Cremer M, Paetzold J, Schmalisch G, Hammer H, Loui A, Dame C et al. Immature platelet fraction as novel laboratory parameter predicting the course of neonatal thrombocytopenia. Br J Haematol 2009; 144: 619-621.
35. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009; 37: 1030-1037.
36. Geddis AE. Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. Hematol Oncol Clin North Am 2009; 23: 321-331.
37. Sola MC, Du Y, Hutson AD, Christensen RD. Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000; 110: 449-453.
38. Sola MC, Christensen RD, Hutson AD, Tarantal AF. Pharmacokinetics, pharmacody-namics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000; 47: 208-214.
39. Pastos KM, Slayton WB, Rimsza LM, Young L, Sola-Visner MC. Differential effects of recombinant thrombopoietin and bone marrow stromal-conditioned media on neonatal versus adult megakaryocytes. Blood 2006; 108: 3360-3362.
40. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007; 78: 183-205.
41. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; 3: CD004863.
42. Dame C, Wolber EM, Freitag P, Hofmann D, Bartmann P, Fandrey J. Thrombopoietin gene expression in the developing human central nervous system. Brain Res Dev Brain Res 2003; 143: 217-223.
43. Ehrenreich H, Hasselblatt M, Knerlich F, von Ahsen N, Jacob S, Sperling S et al. A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. Proc Natl Acad Sci USA 2005; 102: 862-867.
44. Samoylenko A, Byts N, Rajalingam K, von Ahsen N, Rapp UR, Ehrenreich H et al. Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling. Cell Signal 2008; 20: 154-162.
45. Widness JA, Veng-Pedersen P, Modi NB, Schmidt RL, Chestnut DH. Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J Pharmacol Exp Ther 1992; 261: 977-984.